* Vanguard Medica Ltd., of Guildford, England,appointed Gary Acton vice president of clinicaldevelopment, Doreen Wood development projectmanager and Sally Waterman scientific operationsmanager.

* AutoImmune Inc., of Lexington, Mass., appointedMichael Rogers as vice president, chief financial officerand treasurer.

* Cadus Pharmaceutical Corp., of Tarrytown, N.Y.,appointed David Webb to the new position of vicepresident of research and chief scientific officer. Thecompany also appointed Arlindo Castelhano to the newposition of director of chemistry.

* Cambridge Neuroscience Inc., of Cambridge, Mass.,appointed Burkhard Blank as a director. He is anexecutive at Boehringer Ingelheim International GmbH.

* Chugai Pharmaceuticals Inc., of San Diego, namedRobert Roe executive vice president and chief operatingofficer.

* Cortecs Ltd., of London, appointed Leonard Brookes toits board of directors. He joined Cortecs in 1994 asdirector of research and development.

* ESCAgenetics Corp., of San Carlos, Calif., appointedWilliam Koenig as president and chief executive officer.He replaced Richard Moser, who resigned.

* Genelabs Technologies Inc., of Redwood City, Calif.,appointed Irene Chow as CEO. She already waspresident. She succeeds Frank Kung, who will remainchairman.

* GeneMedicine Inc., of The Woodlands, Texas,appointed Richard Waldron as vice president and chieffinancial officer.

* Human Genome Sciences Inc., of Rockville, Md.,elected Max Link to its board of directors. He mostrecently was chief executive officer of CorangeInternational/Boehringer Mannheim.

* Hycor Biomedical Inc., of Irvine, Calif., appointedDavid Thompson to its board of directors. He was anexecutive at Abbott Laboratories and Abbott Diagnostics.

* Matrix Pharmaceutical Inc., of Menlo Park, Calif.,appointed James Glynn to senior vice president and chieffinancial officer.

* Medco Research Inc., of Research Triangle Park,appointed Roger Blevins as president. He was appointedchief operating officer on June 14.

* MicroGeneSys Inc., of Meriden, Conn., appointedArthur Bugs Baer to its board of directors. Baer isdirector of sales for Dunn Capital Management Inc., ofMadison, Conn.

* Targeted Genetics Corp., of Seattle, elected JeremyCook to a new seat on the board of directors. He is adirector of London-based Rothschild Asset ManagementLtd. and International Biotechnology Trust.

* Terrapin Technologies Inc., of South San Francisco,said Clifford Orent assumed responsibilities as chiefexecutive officer. Former CEO Reinaldo Gomezcontinues as an officer and director.

(c) 1997 American Health Consultants. All rights reserved.